{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:01Z","timestamp":1787010121508,"version":"build-2736575974"},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ad.2021.09.005","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T02:04:10Z","timestamp":1640916250000},"page":"376-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Revisi\u00f3n sistem\u00e1tica de los efectos adversos cut\u00e1neos causados por f\u00e1rmacos inhibidores de los puntos de control inmunitario: caracter\u00edsticas, manejo y pron\u00f3stico"],"prefix":"10.1016","volume":"113","author":[{"given":"G.","family":"Juan-Carpena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Palaz\u00f3n-Cabanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Blanes-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2021.09.005_bib0480","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2021.09.005_bib0485","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jaad.2020.03.131","article-title":"Immune checkpoint inhibitors to treat cutaneous malignancies","volume":"83","author":"Barrios","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0490","first-page":"CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ad.2021.09.005_bib0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2020.570752","article-title":"Incidence of skin and respiratory immune-related adverse events correlates with specific tumor types in patients treated with checkpoint inhibitors","volume":"10","author":"Rose","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0500","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: A meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Futur Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0505","doi-asserted-by":"crossref","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int Immunopharmacol."},{"key":"10.1016\/j.ad.2021.09.005_bib0510","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.ad.2021.09.005_bib0515","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2016.02.010","article-title":"Characterization and management of dermatologic adverse events to agents targeting the PD-1 receptor","volume":"60","author":"Belum","year":"2016","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0520","doi-asserted-by":"crossref","first-page":"102983","DOI":"10.1016\/j.critrevonc.2020.102983","article-title":"Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermatological toxicities","volume":"152","author":"Garrett","year":"2020","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.ad.2021.09.005_bib0525","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0530","doi-asserted-by":"crossref","first-page":"e2021155","DOI":"10.5826\/dpc.1101a155","article-title":"Cutaneous adverse events of immune checkpoint inhibitors: A literature review","volume":"11","author":"Apalla","year":"2021","journal-title":"Dermatol Pr Concept."},{"key":"10.1016\/j.ad.2021.09.005_bib0535","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1001\/jamadermatol.2020.2149","article-title":"Association of anti-programmed cell death 1 antibody treatment with risk of recurrence of toxic effects after immune-related adverse events of ipilimumab in patients with metastatic melanoma","volume":"156","author":"Brunot","year":"2020","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0540","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0545","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/cup.12858","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","journal-title":"J Cutan Pathol."},{"key":"10.1016\/j.ad.2021.09.005_bib0550","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0555","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2018.0047","article-title":"New NCCN guidelines: Recognition and management of immunotherapy-related toxicity","volume":"16","author":"Thompson","year":"2018","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.ad.2021.09.005_bib0560","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous Immune-Related Adverse Events (irAEs) to immune checkpoint inhibitors: A dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg."},{"key":"10.1016\/j.ad.2021.09.005_bib0565","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0570","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","article-title":"Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management","volume":"80","author":"Coleman","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0575","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0580","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/jamadermatol.2016.2226","article-title":"Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy","volume":"152","author":"Shi","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0585","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/1759-7714.13275","article-title":"Management of immune checkpoint inhibitor-related dermatologic adverse events","volume":"11","author":"Si","year":"2020","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0590","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/DAD.0000000000000688","article-title":"Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: A detailed examination of the clinicopathologic features","volume":"39","author":"Tetzlaff","year":"2017","journal-title":"Am J Dermatopathol."},{"key":"10.1016\/j.ad.2021.09.005_bib0595","doi-asserted-by":"crossref","DOI":"10.5070\/D3268049884","article-title":"Toxic epidermal necrolysis occurring with immune checkpoint inhibitors","volume":"26","author":"Gopee","year":"2020","journal-title":"Dermatol Online J."},{"key":"10.1016\/j.ad.2021.09.005_bib0600","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3740","article-title":"Bullous pemphigoid associated with anti-programmed cell death protein 1 and anti-programmed cell death ligand 1 therapy: A review of the literature","volume":"101","author":"Tsiogka","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2021.09.005_bib0605","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1200\/JCO.18.02141","article-title":"Treatment outcomes of immune-related cutaneous adverse events","volume":"37","author":"Phillips","year":"2019","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0610","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0615","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMc1805637","article-title":"PD-1 blockade-induced Pruritus treated with a mu-opioid receptor antagonist","volume":"379","author":"Kwatra","year":"2018","journal-title":"N Engl J Med."},{"key":"10.1016\/j.ad.2021.09.005_bib0620","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.lungcan.2017.04.020","article-title":"Aprepitant for refractory nivolumab-induced pruritus","volume":"109","author":"Ito","year":"2017","journal-title":"Lung Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0625","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0630","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.annder.2019.07.008","article-title":"Bullous lichen planus and anti-programmed cell death-1 therapy: Case report and literature review","volume":"147","author":"De Lorenzi","year":"2020","journal-title":"Ann Dermatol Venereol."},{"key":"10.1016\/j.ad.2021.09.005_bib0635","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jaad.2019.06.035","article-title":"Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events","volume":"82","author":"Chan","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0640","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: Clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2021.09.005_bib0645","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jdcr.2020.03.007","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic Merkel cell carcinoma","volume":"6","author":"Kwon","year":"2020","journal-title":"JAAD Case Reports."},{"key":"10.1016\/j.ad.2021.09.005_bib0650","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.clindermatol.2020.06.011","article-title":"Cutaneous immune-related adverse events to checkpoint inhibitors","volume":"38","author":"Malviya","year":"2020","journal-title":"Clin Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dth.14830","article-title":"Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors","volume":"34","author":"Cutroneo","year":"2021","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2021.09.005_bib0660","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-PD1-induced psoriasis: A study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2021.09.005_bib0665","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jaad.2020.08.137","article-title":"Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group","volume":"84","author":"Nikolaou","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0670","doi-asserted-by":"crossref","first-page":"579445","DOI":"10.3389\/fonc.2020.579445","article-title":"Pembrolizumab-induced psoriasis in metastatic melanoma: Activity and safety of apremilast, a case report","volume":"10","author":"Siciliano","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0675","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1078155219877234","article-title":"Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer","volume":"26","author":"Guven","year":"2020","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.ad.2021.09.005_bib0680","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/CJI.0000000000000351","article-title":"Case report and review of 7 similar cases in the literature: Cutaneous sarcoidosis as side effect of pembrolizumab plus chemotherapy in stage iv squamous cell carcinoma of lung","volume":"44","author":"Trilleras-Gomez","year":"2021","journal-title":"J Immunother."},{"key":"10.1016\/j.ad.2021.09.005_bib0685","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12094-020-02546-w","article-title":"Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: Experience in a Spanish hospital","volume":"23","author":"Torres-Jim\u00e9nez","year":"2021","journal-title":"Clin Transl Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0690","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.02.024","article-title":"Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis","volume":"131","author":"Chorti","year":"2020","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0695","doi-asserted-by":"crossref","first-page":"e13074","DOI":"10.1111\/dth.13074","article-title":"Neutrophilic dermatoses as adverse effects of checkpoint inhibitors: A review","volume":"32","author":"Ravi","year":"2019","journal-title":"Dermatol Ther."},{"key":"10.1016\/j.ad.2021.09.005_bib0700","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1177\/1078155220906885","article-title":"Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature","volume":"26","author":"Ya\u015far","year":"2020","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.ad.2021.09.005_bib0705","doi-asserted-by":"crossref","first-page":"e1228","DOI":"10.1634\/theoncologist.2019-0250","article-title":"Serious cutaneous toxicities with immune checkpoint inhibitors in the U.S. Food and Drug Administration adverse event reporting system","volume":"24","author":"Raschi","year":"2019","journal-title":"Oncologist."},{"key":"10.1016\/j.ad.2021.09.005_bib0710","first-page":"1","article-title":"Pembrolizumab-induced Stevens-Johnson Syndrome with severe ocular complications","volume":"7","author":"Ryu","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"key":"10.1016\/j.ad.2021.09.005_bib0715","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/CJI.0000000000000302","article-title":"Combination therapy of ipilimumab and nivolumab-associated toxic epidermal necrolysis (TEN) in a patient with metastatic melanoma: A case report and literature review","volume":"43","author":"Logan","year":"2019","journal-title":"J Immunother."},{"key":"10.1016\/j.ad.2021.09.005_bib0720","first-page":"e183","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: A systematic review","volume":"59","author":"Maloney","year":"2020","journal-title":"Int J Clin Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0725","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: A retrospective analysis","volume":"84","author":"Bui","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0730","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/ced.14449","article-title":"De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: Clinicopathological correlation","volume":"46","author":"Bui","year":"2021","journal-title":"Clin Exp Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0735","doi-asserted-by":"crossref","first-page":"102596","DOI":"10.1016\/j.autrev.2020.102596","article-title":"Risk of scleroderma according to the type of immune checkpoint inhibitors","volume":"19","author":"Terrier","year":"2020","journal-title":"Autoimmun Rev."},{"key":"10.1016\/j.ad.2021.09.005_bib0740","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s40744-020-00246-z","article-title":"Immune checkpoint inhibitor-associated scleroderma-like syndrome: A report of a Pembrolizumab-induced \u201ceosinophilic fasciitis-like\u201d case and a review of the literature","volume":"7","author":"Salamaliki","year":"2020","journal-title":"Rheumatol Ther."},{"key":"10.1016\/j.ad.2021.09.005_bib0745","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1111\/1346-8138.15316","article-title":"Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab","volume":"47","author":"Ogawa-Momohara","year":"2020","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0750","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10637-020-00974-7","article-title":"Anti-transcriptional intermediary factor 1-\u03b3 antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report","volume":"39","author":"Osaki","year":"2021","journal-title":"Invest New Drugs."},{"key":"10.1016\/j.ad.2021.09.005_bib0755","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0760","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0765","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jaad.2020.01.059","article-title":"Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program","volume":"83","author":"Jimenez","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0770","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0775","doi-asserted-by":"crossref","first-page":"588582","DOI":"10.3389\/fimmu.2020.588582","article-title":"Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated cases of Bullous Pemphigoid from six German Dermatology Centers","volume":"11","author":"Sadik","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.ad.2021.09.005_bib0780","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jaad.2020.05.045","article-title":"Management of immune checkpoint inhibitor-induced bullous pemphigoid","volume":"84","author":"Apalla","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0785","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1078155220946370","article-title":"Bullous pemphigoid in elderly woman affected by non-small cell lung cancer treated with pembrolizumab: A case report and review of literature","volume":"27","author":"Cosimati","year":"2021","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.ad.2021.09.005_bib0790","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/ijd.14742","article-title":"Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer","volume":"59","author":"Lee","year":"2020","journal-title":"Int J Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0795","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jaad.2019.08.045","article-title":"BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors","volume":"82","author":"Hasan Ali","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0800","first-page":"30048","article-title":"Bullous pemphigoid after anti-PD-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"10","author":"Nelson","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0805","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0810","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jaad.2020.04.058","article-title":"Cutaneous adverse reactions to anti-PD-1 treatment \u2014A systematic review","volume":"83","author":"Simonsen","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0815","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/imt-2019-0090","article-title":"Aggravation of depigmentation for a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: Case report","volume":"12","author":"Xu","year":"2020","journal-title":"Immunotherapy."},{"key":"10.1016\/j.ad.2021.09.005_bib0820","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.21037\/tlcr-20-386","article-title":"Vitiligo-like depigmentation after pembrolizumab treatment in patients with non-small cell lung cancer: A case report","volume":"9","author":"Yun","year":"2020","journal-title":"Trans Lung Cancer Res."},{"key":"10.1016\/j.ad.2021.09.005_bib0825","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2016.10.044","article-title":"Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo","volume":"76","author":"Larsabal","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0830","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jaad.2019.11.017","article-title":"Vitiligo under anti\u2013programmed cell death-1 therapy is associated with increased survival in melanoma patients","volume":"82","author":"Nardin","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0835","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.esmoop.2021.100064","article-title":"Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: An Italian Melanoma Intergroup study","volume":"6","author":"Guida","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.ad.2021.09.005_bib0840","first-page":"123","article-title":"Cutaneous toxicities of immune checkpoint inhibitors: The role of the dermatologist","volume":"93","author":"Tattersall","year":"2020","journal-title":"Yale J Biol Med."},{"key":"10.1016\/j.ad.2021.09.005_bib0845","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage iii melanoma randomized to receive pembrolizumab or placebo: A secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0850","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/1346-8138.15345","article-title":"Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study","volume":"47","author":"Matsuya","year":"2020","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0855","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/1346-8138.15309","article-title":"Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study","volume":"47","author":"Nakano","year":"2020","journal-title":"J Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0860","first-page":"5597","article-title":"Immunotherapy-mediated dermatological adverse events: The urgent need for a common, clinically meaningful, management strategy","volume":"28","author":"Apalla","year":"2020","journal-title":"Support Care Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0865","first-page":"945","article-title":"Immune-related adverse events and efficacy \u2014The more it hurts, the better it works?","volume":"7","author":"Zhang","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0870","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02612-5","article-title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","volume":"18","author":"Gulati","year":"2020","journal-title":"J Transl Med."},{"key":"10.1016\/j.ad.2021.09.005_bib0875","first-page":"E1","article-title":"Immune-related adverse events and efficacy \u2014The more it hurts, the better it works? Reply","volume":"10","author":"Naidoo","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0880","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0885","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07142-3","article-title":"Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody","volume":"20","author":"Matsuoka","year":"2020","journal-title":"BMC Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0890","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","article-title":"Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study","volume":"79","author":"Min Lee","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.09.005_bib0895","first-page":"156","article-title":"Management of immune-related adverse events affecting outcome in patients treated with checkpoint inhibitors","volume":"72","author":"Suijkerbuijk","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ad.2021.09.005_bib0900","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1078155220929974","article-title":"Bluish-gray fingernail discoloration due to the use of nivolumab","volume":"27","author":"Ocampo","year":"2021","journal-title":"J Oncol Pharm Pract Pract."},{"key":"10.1016\/j.ad.2021.09.005_bib0905","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1177\/1078155216674355","article-title":"Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer","volume":"23","author":"Dasanu","year":"2017","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.ad.2021.09.005_bib0910","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/dermatopathology8010007","article-title":"Anti-PD-1-induced hidradenitis suppurativa","volume":"8","author":"Maillard","year":"2021","journal-title":"Dermatopathol."},{"key":"10.1016\/j.ad.2021.09.005_bib0915","first-page":"1031","article-title":"Acrocyanosis after neoadjuvant Ipilimumab plus nivolumab: A case report","volume":"38","author":"Reijers","year":"2020","journal-title":"Clin Exp Reum."},{"key":"10.1016\/j.ad.2021.09.005_bib0920","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1078155219881181","article-title":"Angioedema late in the course of adjuvant nivolumab therapy for melanoma","volume":"26","author":"Ratra","year":"2020","journal-title":"J Oncol Pharm Pract."},{"key":"10.1016\/j.ad.2021.09.005_bib0925","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2217\/imt-2020-0002","article-title":"Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy","volume":"12","author":"Kersh","year":"2020","journal-title":"Immunotherapy."},{"key":"10.1016\/j.ad.2021.09.005_bib0930","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cup.13604","article-title":"Ipilimumab\/nivolumab-induced pseudolymphoma in a patient with malignant melanoma","volume":"47","author":"Ayoubi","year":"2020","journal-title":"J Cutan Pathol."},{"key":"10.1016\/j.ad.2021.09.005_bib0935","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/1759-7714.13377","article-title":"Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report","volume":"11","author":"Gozzi","year":"2020","journal-title":"Thorac Cancer."},{"key":"10.1016\/j.ad.2021.09.005_bib0940","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2019-0020","article-title":"Radiation recall dermatitis after treatment of stage iv breast cancer with nivolumab: A case report","volume":"12","author":"Billena","year":"2020","journal-title":"Immunotherapy."},{"key":"10.1016\/j.ad.2021.09.005_bib0945","first-page":"101134","article-title":"Nivolumab-induced contact dermatitis in a patient with advanced lung cancer","volume":"30","author":"Sato","year":"2020","journal-title":"Respir Med Case Rep."},{"key":"10.1016\/j.ad.2021.09.005_bib0950","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: A multicenter case series","volume":"83","author":"Molina","year":"2020","journal-title":"J Am Acad Dermatol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021003811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021003811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:12:33Z","timestamp":1757553153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731021003811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0001731021003811"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2021.09.005","relation":{},"ISSN":["0001-7310"],"issn-type":[{"value":"0001-7310","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisi\u00f3n sistem\u00e1tica de los efectos adversos cut\u00e1neos causados por f\u00e1rmacos inhibidores de los puntos de control inmunitario: caracter\u00edsticas, manejo y pron\u00f3stico","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}